-
公开(公告)号：US6083750A
公开(公告)日：2000-07-04
申请号：US245497
申请日：1999-02-05
Applicant: Jeffrey S. Chamberlain , Rajendra Kumar-Singh
Inventor： Jeffrey S. Chamberlain , Rajendra Kumar-Singh
CPC classification number: C12N15/86 , C07K14/4708 , C12N7/00 , A61K48/00 , C12N2710/10343 , C12N2800/30 , C12N2830/008 , C12N2830/30
Abstract: The present invention provides improved adenovirus vectors and packaging cell lines. One type of improved adenoviral vector comprises deletions within the E2b region of the adenoviral genome. These E2b-deleted virus are used in conjunction with novel cell lines that constitutively express E2b gene products. The present invention further provides adenoviral vectors deleted for all viral coding regions. These "gutted" vectors permit the transfer of large genes to cells as demonstrated herein by the transfer of the dystrophin gene to the muscle of mice. The E2b-deleted vectors and the gutted vectors provide improved adenoviral vectors useful for a wide variety of gene therapy applications.
Abstract translation: 本发明提供了改进的腺病毒载体和包装细胞系。 一种类型的改良的腺病毒载体包含在腺病毒基因组的E2b区域内的缺失。 这些E2b缺失的病毒与组成型表达E2b基因产物的新型细胞系一起使用。 本发明还提供了所有病毒编码区缺失的腺病毒载体。 这些“内含”载体允许将大基因转移到细胞中，如本文通过将肌营养不良蛋白基因转移到小鼠的肌肉所证明的。 E2b缺失的载体和内切的载体提供了可用于各种基因治疗应用的改良的腺病毒载体。
-
公开(公告)号：US5994132A
公开(公告)日：1999-11-30
申请号：US735609
申请日：1996-10-23
Applicant: Jeffrey S. Chamberlain , Rajendra Kumar-Singh
Inventor： Jeffrey S. Chamberlain , Rajendra Kumar-Singh
CPC classification number: C12N15/86 , C07K14/4708 , C12N7/00 , A61K48/00 , C12N2710/10343 , C12N2800/30 , C12N2830/008 , C12N2830/30
Abstract: The present invention provides improved adenovirus vectors and packaging cell lines. One type of improved adenoviral vector comprises deletions within the E2b region of the adenoviral genome. These E2b-deleted virus are used in conjunction with novel cell lines that constitutively express E2b gene products. The present invention further provides adenoviral vectors deleted for all viral coding regions. These "gutted" vectors permit the transfer of large genes to cells as demonstrated herein by the transfer of the dystrophin gene to the muscle of mice. The E2b-deleted vectors and the gutted vectors provide improved adenoviral vectors useful for a wide variety of gene therapy applications.
-
公开(公告)号：US06451596B1
公开(公告)日：2002-09-17
申请号：US09562919
申请日：2000-05-02
Applicant: Jeffrey S. Chamberlain , Andrea Amalfitano , Michael A. Hauser , Rajendra Kumar-Singh , Denis J. Hartigan-O'Connor
Inventor： Jeffrey S. Chamberlain , Andrea Amalfitano , Michael A. Hauser , Rajendra Kumar-Singh , Denis J. Hartigan-O'Connor
IPC: C12N1586
CPC classification number: C12N15/86 , A61K48/00 , C07K14/4708 , C12N7/00 , C12N2710/10343 , C12N2800/30 , C12N2830/008 , C12N2830/30
Abstract: The present invention provides improved adenovirus vectors and packaging cell lines. One type of improved adenoviral vector comprises deletions within the E2b region of the adenoviral genome. These E2b-deleted virus are used in conjunction with novel cell lines that constitutively express E2b gene products. The present invention further provides adenoviral vectors deleted for all viral coding regions. These “gutted” vectors permit the transfer of large genes to cells as demonstrated herein by the transfer of the dystrophin gene to the muscle of mice. The E2b-deleted vectors and the gutted vectors provide improved adenoviral vectors useful for a wide variety of gene therapy applications.
Abstract translation: 本发明提供了改进的腺病毒载体和包装细胞系。 一种类型的改良的腺病毒载体包含在腺病毒基因组的E2b区域内的缺失。 这些E2b缺失的病毒与组成型表达E2b基因产物的新型细胞系一起使用。 本发明还提供了所有病毒编码区缺失的腺病毒载体。 这些“内含”载体允许将大基因转移到细胞中，如本文通过将肌营养不良蛋白基因转移到小鼠的肌肉所证明的。 E2b缺失的载体和内切的载体提供了可用于各种基因治疗应用的改良的腺病毒载体。
-
公开(公告)号：US08637313B2
公开(公告)日：2014-01-28
申请号：US12884027
申请日：2010-09-16
Applicant: Jeffrey S. Chamberlain , Dennis J. Hartigan-O'Connor
Inventor： Jeffrey S. Chamberlain , Dennis J. Hartigan-O'Connor
CPC classification number: C12N15/86 , C12N2710/10043 , C12N2710/10322 , C12N2710/10343 , C12N2710/10351 , C12N2800/30 , C12N2830/002 , C12N2830/38
Abstract: The present invention relates to methods and compositions for the production of viral vectors. In particular, the present invention provides methods and compositions for faster, higher titer and higher purity production of viral vectors (e.g. adenoviral vectors). In some embodiments, the present invention provides gutted and helper viruses with identical or similar termini. In other embodiments, the present invention provides terminal protein linked adenoviral DNA. In certain embodiments, the present invention provides template extended adenoviral DNA.
Abstract translation: 本发明涉及用于生产病毒载体的方法和组合物。 特别地，本发明提供了用于更快，更高滴定度和更高纯度产生病毒载体（例如腺病毒载体）的方法和组合物。 在一些实施方案中，本发明提供具有相同或相似末端的内切和辅助病毒。 在其它实施方案中，本发明提供了末端蛋白质连接的腺病毒DNA。 在某些实施方案中，本发明提供扩增模板的腺病毒DNA。
-
公开(公告)号：US06869777B2
公开(公告)日：2005-03-22
申请号：US10149736
申请日：2001-10-04
Applicant: Jeffrey S. Chamberlain , Scott Q. Harper
Inventor： Jeffrey S. Chamberlain , Scott Q. Harper
CPC classification number: C07K14/4708 , A01K2217/05 , A61K48/00 , C12N2799/022
Abstract: The present invention relates to compositions and methods for expressing mini-dystrophin peptides. In particular, the present invention provides compositions comprising nucleic acid sequences that are shorter than wild-type dystrophin cDNA and that express mini-dystrophin peptides that function in a similar manner as wild-type dystrophin proteins. The present invention also provides compositions comprising mini-dystrophin peptides, and methods for expressing mini-dystrophin peptides in target cells.
Abstract translation: 本发明涉及用于表达微型肌营养不良蛋白肽的组合物和方法。 特别地，本发明提供了包含比野生型肌营养不良蛋白cDNA短的核酸序列并且表达与野生型肌营养不良蛋白类似的功能的微型肌营养不良蛋白肽的组合物。 本发明还提供了包含迷你抗肌营养不良蛋白肽的组合物，以及用于在靶细胞中表达微型肌营养不良蛋白肽的方法。
-
Patent Agency Ranking
公开(公告)号：US06063622A
公开(公告)日：2000-05-16
申请号：US244752
申请日：1999-02-05
Applicant: Jeffrey S. Chamberlain , Andrea Amalfitano
Inventor： Jeffrey S. Chamberlain , Andrea Amalfitano
CPC classification number: C12N15/86 , C07K14/4708 , C12N7/00 , A61K48/00 , C12N2710/10343 , C12N2800/30 , C12N2830/008 , C12N2830/30
Abstract: The present invention provides improved adenovirus vectors and packaging cell lines. One type of improved adenoviral vector comprises deletions within the E2b region of the adenoviral genome. These E2b-deleted virus are used in conjunction with novel cell lines that constitutively express E2b gene products. The present invention further provides adenoviral vectors deleted for all viral coding regions. These "gutted" vectors permit the transfer of large genes to cells as demonstrated herein by the transfer of the dystrophin gene to the muscle of mice. The E2b-deleted vectors and the gutted vectors provide improved adenoviral vectors useful for a wide variety of gene therapy applications.
-
公开(公告)号：US5582989A
公开(公告)日：1996-12-10
申请号：US315673
申请日：1994-09-30
Applicant: Charles T. Caskey , Jeffrey S. Chamberlain , Richard A. L. Gibbs , Joel E. Ranier , Phi N. Nguyen
Inventor： Charles T. Caskey , Jeffrey S. Chamberlain , Richard A. L. Gibbs , Joel E. Ranier , Phi N. Nguyen
CPC classification number: C12Q1/6883 , C07K14/4708 , C12Q1/6858 , C12Q1/686 , C12Q2600/156 , C12Q2600/16
Abstract: The present invention relates to a method for detecting multiple DNA sequences simultaneously. The method involves amplification of multiple sequences simultaneously by annealing a plurality of paired oligonucleotide primers to single stranded DNA. One member of each pair is complementary to the sense strand of a sequences and the other member is complementary to a different segment of the anti-sense strand of the same sequence. The amplification occurs by alternately annealing and extending the primers. The invention also includes oligonucleotide primer sequences helpful in detecting genetic diseases and/or exogenous DNA sequences.
Abstract translation: 本发明涉及同时检测多个DNA序列的方法。 该方法包括通过将多个成对寡核苷酸引物退火至单链DNA同时扩增多个序列。 每对中的一个成员与序列的有义链互补，另一个成员与相同序列的反义链的不同片段互补。 通过交替退火和扩展引物进行扩增。 本发明还包括有助于检测遗传疾病和/或外源DNA序列的寡核苷酸引物序列。
-
8.发明授权Nucleic acid sequences encoding peptides with utrophin spectrin-like repeats 有权编码具有utrophin spectrin样重复肽的核酸序列公开(公告)号：US08501920B2
公开(公告)日：2013-08-06
申请号：US11824870
申请日：2007-07-03
Applicant: Jeffrey S. Chamberlain , Scott Q. Harper
Inventor： Jeffrey S. Chamberlain , Scott Q. Harper
CPC classification number: C07K14/4708 , A01K2217/05 , A61K48/00 , C12N2799/022
Abstract: The present invention relates to compositions and methods for expressing mini-dystrophin peptides. In particular, the present invention provides compositions comprising nucleic acid sequences that are shorter than wild-type dystrophin cDNA and that express mini-dystrophin peptides that function in a similar manner as wild-type dystrophin proteins. The present invention also provides compositions comprising mini-dystrophin peptides, and methods for expressing mini-dystrophin peptides in target cells.
Abstract translation: 本发明涉及用于表达微型肌营养不良蛋白肽的组合物和方法。 特别地，本发明提供了包含比野生型肌营养不良蛋白cDNA短的核酸序列并且表达与野生型肌营养不良蛋白类似的功能的微型肌营养不良蛋白肽的组合物。 本发明还提供了包含迷你抗肌营养不良蛋白肽的组合物，以及用于在靶细胞中表达微型肌营养不良蛋白肽的方法。
-
公开(公告)号：US20110033926A1
公开(公告)日：2011-02-10
申请号：US12884027
申请日：2010-09-16
Applicant: Jeffrey S. Chamberlain , Dennis J. Hartigan-O'Connor
Inventor： Jeffrey S. Chamberlain , Dennis J. Hartigan-O'Connor
CPC classification number: C12N15/86 , C12N2710/10043 , C12N2710/10322 , C12N2710/10343 , C12N2710/10351 , C12N2800/30 , C12N2830/002 , C12N2830/38
Abstract: The present invention relates to methods and compositions for the production of viral vectors. In particular, the present invention provides methods and compositions for faster, higher titer and higher purity production of viral vectors (e.g. adenoviral vectors). In some embodiments, the present invention provides gutted and helper viruses with identical or similar termini. In other embodiments, the present invention provides terminal protein linked adenoviral DNA. In certain embodiments, the present invention provides template extended adenoviral DNA.
Abstract translation: 本发明涉及用于生产病毒载体的方法和组合物。 特别地，本发明提供了用于更快，更高滴定度和更高纯度产生病毒载体（例如腺病毒载体）的方法和组合物。 在一些实施方案中，本发明提供具有相同或相似末端的内切和辅助病毒。 在其它实施方案中，本发明提供了末端蛋白质连接的腺病毒DNA。 在某些实施方案中，本发明提供扩增模板的腺病毒DNA。
-
公开(公告)号：US09868937B2
公开(公告)日：2018-01-16
申请号：US14122226
申请日：2012-05-29
Applicant: Michael Regnier , Michael Laflamme , Charles Murry , F. Steven Korte , Scott Lundy , Stephen Denison Hauschka , Jeffrey S. Chamberlain , Guy Odom
Inventor： Michael Regnier , Michael Laflamme , Charles Murry , F. Steven Korte , Scott Lundy , Stephen Denison Hauschka , Jeffrey S. Chamberlain , Guy Odom
IPC: C12N5/077 , C12N9/02 , A01K67/027 , A61K48/00 , C07K14/47 , C12N15/85 , A61K9/00 , A61K35/34 , C12N7/00 , C12N15/86
CPC classification number: C12N5/0657 , A01K67/0275 , A01K2217/052 , A01K2227/105 , A01K2267/0375 , A61K9/0019 , A61K35/34 , A61K48/005 , C07K14/4716 , C12N7/00 , C12N9/0093 , C12N15/8509 , C12N15/86 , C12N2750/14132 , C12N2750/14143 , C12N2799/022 , C12N2799/025 , C12Y117/04001 , C12Y117/04002
Abstract: Compositions and methods for improving cardiac function, myocardial contractility and relaxation in a mammal are provided. Cardiomyocytes transfected with one or more expression vectors comprising a ribonucleotide reductase subunit R1-encoding nucleic acid sequence and a ribonucleotide reductase subunit R2-encoding nucleic acid sequence operably linked to a promoter are grafted to a mammalian myocardium. Also provided are compositions and methods for delivering dATP to a myocardium through grafting of donor cells overexpressing R1 and R2. dATP is thereby produced in situ and delivered through gap junctions established between donor cells and host cardiomyocytes. Alternatively, viral vector(s) having the R1 and R2-encoding construct(s) are administered to the mammal directly. Improvement of cardiac function can also be effected by administration of vectors comprising a nucleic acid sequence encoding a L48Q, 61 Q, or L57Q cTnC variant.
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.034 seconds)
